| Peer-Reviewed

Clinical Presentation and Biological Modification of Hospitalized Patients for COVID-19 in the Democratic Republic of Congo

Received: 9 March 2022    Accepted: 25 March 2022    Published: 24 May 2022
Views:       Downloads:
Abstract

Background and aims: the whole of humanity has experienced since December 2019 a pandemic of coronavirus disease 2019 (COVID-19), caused by the coronavirus. Unprecedented situation in this century especially for the DR Congo with a less equipped health system. The objective of this study is to describe the clinico-biological profile of patients hospitalized at the Cinquantenaire Hospital of Kinshasa in DR Congo. Methods: This was a retrospective, analytical and descriptive cohort study carried out among 360 patients hospitalized at the Cinquantenaire Hospital in Kinshasa from the period from April 18, 2020 to July 10, 2021. Results: The average age was 42.7 ± 12.0 years with a female predominance, 57.7% of patients were over 50 years old. Comorbidities such as hypertension, diabetes mellitus and bronchial asthma were present respectively in 25.2% and 4.2% and 12.3%. The symptomatology was dominated by cough, fever and asthenia in more than The most common biological abnormalities were as follows: increased CRP (57.7%), basocytaemia (55%), hepatic cytolysis (20.6%), elevated D-dimer (15.3%), decreased TP (17.5%) lymphopenia (16.7%), anemia (11.1%) and Hyperleukocytosis 10.6% Conclusion: COVID-19 infection should be considered as sepsis with multi-visceral involvement although the lung is first. Both biological and hematological abnormalities may be encountered.

Published in American Journal of Internal Medicine (Volume 10, Issue 3)
DOI 10.11648/j.ajim.20221003.14
Page(s) 56-61
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

COVID-19, Symptoms, Biology

References
[1] Lu H, Stratton C, Tang Y. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020 Jan 16.
[2] Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020; 91 (1): 157-160.
[3] Wu Y, Chen C, Chan Y. Overview of the 2019 novel coronavirus (2019-nCoV): the pathogen of severe specific contagious pneumonia (SSCP). J Chin Med Assoc. 2020.
[4] Wu, Z. and McGoogan, J.. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020; 323, 1239–1242.
[5] World Health Organization. Coronavirus disease (COVID-19). World Health Organization. October 11, 2020.
[6] Wimba M, Bazeboso J, Katchunga B et al. A dashboard for monitoring preventive measures in response to COVID-19 outbreak in the Democratic Republic of Congo. Tropical Medicine and Health. 2020; 48: 74.
[7] Pan Y, Li X, Yang G et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infected. 2020 Apr 10; 81 (1): e28-e32.
[8] Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020 May 6. Epub 2020/05/07.
[9] Shi H, Han X, Jiang N et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20 (4): 425-34.
[10] Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13; e200994.
[11] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-62.
[12] Placais L, Richier Q. COVID-19: clinical, biological and radiological characteristics in adults, infants and pregnant women. An up-to-date review at the heart of the pandemic. Internal Rev Med. 2020; 41 (5): 308-18. PubMed | Google Scholar.
[13] Ben Izizag Bepouka, Madone Mandina, Jean Robert Makulo, Murielle Longokolo, Ossam Odio, Nadine Mayasi, Tresor Pata, et al. Predictors of mortality in COVID-19 patients at Kinshasa University Hospital, Democratic Republic of the Congo, from March to June 2020. Pan African Medical Journal. 2020; 37 (105).
[14] Bottiger LE, Svedberg CA. Normal erythrocyte sedimentation rate and age. Br Med J. 1967; 2 (5544): 85-7.
[15] Haeckel R. Simplified determinations of the "true" creatinine concentration in serum and urine. J Clin Chem Clin Biochem. 1980; 18 (7): 385-94.
[16] Lessinger JM, Ferard G, Grafmeyer D, Labbe D, Maire I, Schiele F et al. Improvement of result consistency in clinical enzymology: multicenter study of gamma-glutamyltransferase, alkaline phosphatase and amylase activities. Ann Biol Clin (Paris). 1995; 53 (3): 147-54.
[17] Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am. 1997; 81 (3): 585-609.
[18] Gordon JS, Wood CT, Luc JGY, Watson RA, Maynes EJ, Choi JH et al. Clinical implications of LDH isoenzymes in hemolysis and continuous-flow left ventricular assist device-induced thrombosis. Artif Organs. 2020; 44 (3): 231-8.
[19] Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB et al. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Traffic. 2007; 115 (13): e356-75.
[20] Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006; 367 (9508): 404-11.
[21] Colombet I, Pouchot J, Kronz V, Hanras X, Capron L, Durieux P et al. Agreement between erythrocyte sedimentation rate and C-reactive protein in hospital practice. Am J Med. 2010 Sep; 123 (9): 863. e7-13.
[22] Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020; ntaa082.
[23] Louhaichi S, Allouche A, Baili H et al. Features of patients with 2019 novel coronavirus admitted in a pneumology department: The first retrospective Tunisian case series. Tunis Med. 2020; 98 (4): 261-5.
[24] Rodriguez A, Cardona J, Gutierrez E et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020; 34: 101623.
[25] Paules C, Marston H, Fauci A. Coronavirus infections-more than just the common cold. Jama. 2020; 323: 707-8.
[26] Cinaud A, Sorbets E, Blanchier V et al. high blood pressure and COVID-19. The Medical Training Press. 2021; 2 (1): 25-32.
[27] Raiah M, Terki K, Benrabach et al. Dynamic changes in the demographic and clinical characteristics of patients with COVID-19 in Algeria. Batna J Med sci 2022; 9 (S1): 17-21.
[28] Vardaras C and Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis, 2020; 18: 20.
[29] Liu W, Tao Z, Lei et al. Analysis of factors associated with disease outcomes in hospitalized with 2019 novel coronavisus disease. Chin. Med J. 2020; 133 (9): 1032-1038.
[30] Beli R, Louhaichi S, Ammar J et al. COVID-19 and smoking: what are the particularities? Respiratory Disease Rev. 2022; 14 (1): 111.
[31] Almirall J, Gonzalez C, Balanzo X et al. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest. 1999; 116: 375-9.
[32] Guan W, Ni Z, Hu Y et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-20. pneumonia. Invest Radiol. 2020; 55 (6): 327-31.
[33] Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan; china. JAMA. 2020; 323: 1061-1069.
[34] Marnell L, Moule C and Clos T. C-reactive protein: ligands, receptors and role in inflammation. Clin. 2005; 117 (2): 104-111.
[35] Chen Y and Li L. SARS-CoV-2: Virus dynamics and host response. Lancet Infect Dis. 2020; 20: 515-516.
[36] Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 10236.
[37] Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the Coronavirus Disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; 75: 2352-71.
[38] Yu B, Li X, Chen J, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis 2020; 50: 548-557.
[39] Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta Int J Clin Chem 2020; 506: 145—8.
[40] Li K, Wu J, Wu F, et al. The Clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol. 2020; 55 (6): 327-31.
Cite This Article
  • APA Style

    Blaise Makoso Nimi, Benjamin Longo Mbenza, Timothee Mawisa Nkemfuni, Steve Tulantched Mingana, Gaston Katomba Zeba, et al. (2022). Clinical Presentation and Biological Modification of Hospitalized Patients for COVID-19 in the Democratic Republic of Congo. American Journal of Internal Medicine, 10(3), 56-61. https://doi.org/10.11648/j.ajim.20221003.14

    Copy | Download

    ACS Style

    Blaise Makoso Nimi; Benjamin Longo Mbenza; Timothee Mawisa Nkemfuni; Steve Tulantched Mingana; Gaston Katomba Zeba, et al. Clinical Presentation and Biological Modification of Hospitalized Patients for COVID-19 in the Democratic Republic of Congo. Am. J. Intern. Med. 2022, 10(3), 56-61. doi: 10.11648/j.ajim.20221003.14

    Copy | Download

    AMA Style

    Blaise Makoso Nimi, Benjamin Longo Mbenza, Timothee Mawisa Nkemfuni, Steve Tulantched Mingana, Gaston Katomba Zeba, et al. Clinical Presentation and Biological Modification of Hospitalized Patients for COVID-19 in the Democratic Republic of Congo. Am J Intern Med. 2022;10(3):56-61. doi: 10.11648/j.ajim.20221003.14

    Copy | Download

  • @article{10.11648/j.ajim.20221003.14,
      author = {Blaise Makoso Nimi and Benjamin Longo Mbenza and Timothee Mawisa Nkemfuni and Steve Tulantched Mingana and Gaston Katomba Zeba and Piroger Phoba Mbadu and Firmin Mbambi Nsungu and Fabrice Nlandu Makungu and Christian Kisoka Lusunsi},
      title = {Clinical Presentation and Biological Modification of Hospitalized Patients for COVID-19 in the Democratic Republic of Congo},
      journal = {American Journal of Internal Medicine},
      volume = {10},
      number = {3},
      pages = {56-61},
      doi = {10.11648/j.ajim.20221003.14},
      url = {https://doi.org/10.11648/j.ajim.20221003.14},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20221003.14},
      abstract = {Background and aims: the whole of humanity has experienced since December 2019 a pandemic of coronavirus disease 2019 (COVID-19), caused by the coronavirus. Unprecedented situation in this century especially for the DR Congo with a less equipped health system. The objective of this study is to describe the clinico-biological profile of patients hospitalized at the Cinquantenaire Hospital of Kinshasa in DR Congo. Methods: This was a retrospective, analytical and descriptive cohort study carried out among 360 patients hospitalized at the Cinquantenaire Hospital in Kinshasa from the period from April 18, 2020 to July 10, 2021. Results: The average age was 42.7 ± 12.0 years with a female predominance, 57.7% of patients were over 50 years old. Comorbidities such as hypertension, diabetes mellitus and bronchial asthma were present respectively in 25.2% and 4.2% and 12.3%. The symptomatology was dominated by cough, fever and asthenia in more than The most common biological abnormalities were as follows: increased CRP (57.7%), basocytaemia (55%), hepatic cytolysis (20.6%), elevated D-dimer (15.3%), decreased TP (17.5%) lymphopenia (16.7%), anemia (11.1%) and Hyperleukocytosis 10.6% Conclusion: COVID-19 infection should be considered as sepsis with multi-visceral involvement although the lung is first. Both biological and hematological abnormalities may be encountered.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Clinical Presentation and Biological Modification of Hospitalized Patients for COVID-19 in the Democratic Republic of Congo
    AU  - Blaise Makoso Nimi
    AU  - Benjamin Longo Mbenza
    AU  - Timothee Mawisa Nkemfuni
    AU  - Steve Tulantched Mingana
    AU  - Gaston Katomba Zeba
    AU  - Piroger Phoba Mbadu
    AU  - Firmin Mbambi Nsungu
    AU  - Fabrice Nlandu Makungu
    AU  - Christian Kisoka Lusunsi
    Y1  - 2022/05/24
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ajim.20221003.14
    DO  - 10.11648/j.ajim.20221003.14
    T2  - American Journal of Internal Medicine
    JF  - American Journal of Internal Medicine
    JO  - American Journal of Internal Medicine
    SP  - 56
    EP  - 61
    PB  - Science Publishing Group
    SN  - 2330-4324
    UR  - https://doi.org/10.11648/j.ajim.20221003.14
    AB  - Background and aims: the whole of humanity has experienced since December 2019 a pandemic of coronavirus disease 2019 (COVID-19), caused by the coronavirus. Unprecedented situation in this century especially for the DR Congo with a less equipped health system. The objective of this study is to describe the clinico-biological profile of patients hospitalized at the Cinquantenaire Hospital of Kinshasa in DR Congo. Methods: This was a retrospective, analytical and descriptive cohort study carried out among 360 patients hospitalized at the Cinquantenaire Hospital in Kinshasa from the period from April 18, 2020 to July 10, 2021. Results: The average age was 42.7 ± 12.0 years with a female predominance, 57.7% of patients were over 50 years old. Comorbidities such as hypertension, diabetes mellitus and bronchial asthma were present respectively in 25.2% and 4.2% and 12.3%. The symptomatology was dominated by cough, fever and asthenia in more than The most common biological abnormalities were as follows: increased CRP (57.7%), basocytaemia (55%), hepatic cytolysis (20.6%), elevated D-dimer (15.3%), decreased TP (17.5%) lymphopenia (16.7%), anemia (11.1%) and Hyperleukocytosis 10.6% Conclusion: COVID-19 infection should be considered as sepsis with multi-visceral involvement although the lung is first. Both biological and hematological abnormalities may be encountered.
    VL  - 10
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Department of Internal Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo

  • Department of Internal Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo

  • Department of Anesthesia and Resuscitation, Cinquantenaire Hospital, Kinshasa, Democratic Republic of Congo

  • Department of Anesthesia and Resuscitation, Cinquantenaire Hospital, Kinshasa, Democratic Republic of Congo

  • Department of Internal Medicine, University of President Joseph Kasa-Vubu, Boma, Democratic Republic of Congo

  • Department of Internal Medicine, University of President Joseph Kasa-Vubu, Boma, Democratic Republic of Congo

  • Department of Internal Medicine, University of President Joseph Kasa-Vubu, Boma, Democratic Republic of Congo

  • Department of Internal Medicine, University of President Joseph Kasa-Vubu, Boma, Democratic Republic of Congo

  • Departement of Public Health, Lomo-University Research, Kinshasa, Democratic Republic of Congo

  • Sections